Citadel Advisors
ORIC icon

Citadel Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Citadel Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,700
Closed -$15.1K – 14360
2025
Q1 		$15.1K Sell
2,700
-3,700
-58% -$32.4K ﹤0.01% 13335
2024
Q4 		$51.6K Buy
6,400
+5,700
+814% +$52.3K ﹤0.01% 12361
2024
Q3 		$7.17K Buy
+700
New +$6.92K ﹤0.01% 13379
2024
Q2 		– Sell
-7,700
Closed -$106K – 15070
2024
Q1 		$106K Buy
+7,700
New +$91.5K ﹤0.01% 11273
2023
Q3 		– Sell
-1,800
Closed -$14K – 14859
2023
Q2 		$14K Sell
1,800
-5,600
-76% -$31.8K ﹤0.01% 13020
2023
Q1 		$42.2K Buy
7,400
+2,600
+54% +$13.6K ﹤0.01% 12377
2022
Q4 		$28.3K Sell
4,800
-15,900
-77% -$53.7K ﹤0.01% 12806
2022
Q3 		$66K Sell
20,700
-1,700
-8% -$6.81K ﹤0.01% 11426
2022
Q2 		$100K Buy
+22,400
New +$89.4K ﹤0.01% 11414

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Citadel Advisors's ORIC Position: Q1 2026 in Review

Citadel Advisors reduced its Oric Pharmaceuticals (ORIC) stake by 0.49% in Q1 2026, selling an estimated $136K and leaving 2,422,741 shares worth $30.7M. The position accounts for 0.01% of the portfolio, ranked #1843.

Citadel Advisors first reported a position in ORIC in Q2 2020 and has held it in 19 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Citadel Advisors held 2,422,741 shares of Oric Pharmaceuticals worth $30.7M as of Q1 2026.
  • Citadel Advisors sold 11,969 Oric Pharmaceuticals shares in Q1 2026, an estimated $136K.
  • Oric Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1843 holding.
  • Citadel Advisors first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.